New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

Findings suggest that revisions to immunization policies could strengthen productivity, equitable access, and the long-term health of Japan’s older adults 

Tokyo, JAPAN and New York, NEW YORK (March 5, 2026) -The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines. Its findings suggest that Japan is not realizing the full benefits of adult vaccines, with the current adult vaccine policy framework placing a disproportionate burden on fiscally constrained local governments and individuals, undermining equitable access. Among other recommendations, the report calls for Japanese decisionmakers to reexamine how diseases are categorized and included in the national immunization schedule. 

“Japan’s current vaccine program leaves much of its implementation to local governments, and as a result, challenges around access are beginning to be discussed in some areas. As a super-aged society, the country needs to move toward proactive prevention, driven by stronger leadership, with a focus on promoting healthy longevity. HGPI believes it is important to address these challenges through constructive dialogue among all stakeholders.” explained Ryoji Noritake, Chair of the Tokyo-based Health and Global Policy Institute, one of the organizations behind the new report. 

The report calls on leaders to (1) clarify conditions for inclusion in the routine immunization schedule and review the positioning of one or more Category B diseases under the Immunization Act; (2) unify national and local financing mechanisms to eliminate disparities in vaccination access across municipalities; and (3) strengthen preventive health policies to sustain Japan’s healthcare system and advance its silver economy through higher adult vaccination rates. 

These proposed changes will support Japan’s global leadership on universal health coverage and health equity, strengthen the efficiency of the health system, and support continued growth. “In countries like Japan, where older adults represent an increasing share of the workforce, the effective use of preventive health tools like adult vaccines reduces avoidable healthcare spending and supports greater productivity, contributing to overall economic growth” said Michael Hodin, CEO of the Global Coalition on Aging and a global thought leader on aging-related policy.  

To advance the dialogue on vaccine policy for Japan, GCOA and AP-CHAAI, in collaborationwith HGPI, will bring together global, regional, and local policymakers, experts, healthcare practitioners, and researchers, on March 11, for a private convening in Tokyo to discuss the role of adult vaccines in advancing healthy aging and economic growth both in Japan and throughout aging Asia.  

 

For more information, please contact: 

Susan Schwarz / Global Coalition on Aging 

[email protected]

About the Health and Global Policy Institute  

Health and Global Policy Institute (HGPI) is an independent non-profit, non-partisan think tank established in 2004. Since its establishment, HGPI has worked to organize extensive discussions with a wide range of stakeholders on the pressing health policy issues, and to offer policy options to society. HGPI is committed to the goal of promoting effective health policy choices for Japan and addressing today’s global health issues through cooperation with a wide range of stakeholders. 

About the Asia-Pacific Consortium for Healthy Aging and Adult Immunization  

The Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) is a pioneering initiative dedicated to improving adult vaccine access and uptake across the Asia-Pacific region. By bringing together leading public and private sector experts, AP-CHAAI aims to break through the knowledge and policy barriers that hinder adult immunization, which pose a growing threat to healthy aging. 

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.